What are You Looking For?

Nine9cr
onOctober 9, 2025

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

1 min read

Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fatal liver disease.

Nine9cr
onOctober 9, 2025
6 views
Share
Previous Article

Social Security’s COLA increase could jump to 2.8% next year. That still isn’t enough for people to get by.

Next Article

Macron Will Name New Prime Minister, Averting Snap Election & Further Political Turmoil 

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

+ 48 = 55
Powered by MathCaptcha

Read Next

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨